Posts

Posted on

Fit for the COVID Fight: GE Healthcare Expands Ultrasound Family with New Point of Care System and AI Offering

Fit for the COVID Fight: GE Healthcare Expands Ultrasound Family with New Point of Care System and AI Offering

CHICAGO–(BUSINESS WIRE)–
Driven by pandemic realities and clinical demand for portable and intelligent point-of-care ultrasound (POCUS), GE Healthcare today unveiled Venue Fit™, a streamlined and compact POCUS system, alongside an industry-first AI offering for cardiac imaging on the Venue™ and Venue Go™. The Venue Fit is the smallest system in GE Healthcare’s Venue Family, featuring an easy-to-clean touchscreen, intuitive scanning tools, and a small footprint designed to fit in tight spaces often found in point-of-care settings.

The Venue Fit and associated AI come at a time where clinicians are relying on point of care ultrasound to combat the more than 127 million COVID-19 cases worldwide.1 Offering portability, real-time images, cleanability and workflow efficiency, POCUS has become an essential tool enabling clinicians to quickly triage and monitor patients in and outside of COVID wards. Accordingly, GE Healthcare saw orders for its existing Venue Go system increase more than fivefold in 2020 compared to the year prior.2

“COVID-19 has had a huge impact on my practice as we’re currently seeing a surge in the emergency department, and I’ve been taking my Venue Go with me everywhere I go,” said Dr. Joseph Minardi, Chief of the Division of Emergency and Clinical Ultrasound and Director of the Center for Point-of-Care Ultrasound at a West Virginia academic medical center. “With the new Venue tools, I don’t have to struggle with the interface to be efficient. I can bring the device in with me, scan the patient, and using the Lung Sweep and RealTime EF (ejection fraction), I have the information I need right away.”

The new Venue Fit ultrasound system helps meet the needs of providers in tight spaces needing quick imaging insights. It’s smaller in size, but still provides the same Venue Family image quality, touchscreen, intuitive interface, and real-time documentation software that can save time and boost clinical confidence.

In addition to the release of the Venue Fit, the existing Venue Go and Venue ultrasound systems will now offer an industry-first AI tool for cardiac scanning with an integrated quality indicator, RealTime EF, alongside new software applications:

  • RealTime EF, the industry’s first AI tool that continuously calculates the heart’s real-time ejection fraction, a measurement of the heart’s ability to pump blood effectively, during live scanning with an integrated quality indicator that helps users know when they have an adequate view to generate accurate measurements of this critical cardiac measurement. The tool can help reduce the need for ECGs and support clinical confidence.
  • Lung Sweep, a rapid visualization tool that provides a dynamic panoramic view of the entire lung. This tool automatically activates at the start of each sweep when the probe is tapped on the body and deactivates at the end of each sweep when the probe is lifted, so there’s no need to touch the screen. The Auto B-lines tool can be used in conjunction with Lung Sweep to highlight B-lines over the entire panoramic view and display the frame with the most B-lines per rib space.
  • Renal Diagram, a simplified, intelligent documentation tool that allows clinicians to select labels from a prepopulated list that correlates with the images captured, making it easy for other clinicians to follow up on patients with suspected kidney infection.

“This past year we’ve seen point of care ultrasound take a prominent place at the bedside for clinicians, driven by its intuitive design and AI-powered diagnostic prowess,” said Dietmar Seifriedsberger, general manager of Point of Care Ultrasound at GE Healthcare. “Understanding healthcare’s growing resource constraints and the challenges of today’s world, we’re expanding our Venue Family and offerings to help improve our customer’s workflow efficiency and diagnostic confidence.”

For information about the Venue Fit, the new software offerings, and to access the Venue Family interactive educational platform visit: https://venue-pocus.gehealthcare.com/

About GE Healthcare:

GE Healthcare is the $18 billion healthcare business of GE (NYSE: GE). As a leading global medical technology and digital solutions innovator, GE Healthcare enables clinicians to make faster, more informed decisions through intelligent devices, data analytics, applications and services, supported by its Edison intelligence platform. With over 100 years of healthcare industry experience and around 50,000 employees globally, the company operates at the center of an ecosystem working toward precision health, digitizing healthcare, helping to drive productivity and improve outcomes for patients, providers, health systems and researchers around the world. Follow us on Facebook, LinkedIn, Twitter and Insights, or visit our website www.gehealthcare.com for more information.

 

1 Accessed on 2/8/2021: https://coronavirus.jhu.edu/map.html

2 GE Healthcare Data on File

Media Contact:

Kate Rodgers

[email protected]

+262 202 5430

KEYWORDS: United States North America Illinois

INDUSTRY KEYWORDS: Technology Biotechnology Diabetes Health Radiology Other Technology Research Medical Devices Infectious Diseases Hospitals Hardware Science Cardiology Medical Supplies

MEDIA:

Logo
Logo
Posted on

ContactEngine Partners with Vonage to Enhance Customer Experience and International Reach

ContactEngine Partners with Vonage to Enhance Customer Experience and International Reach

ContactEngine provides leading proactive conversational AI capabilities, taps Vonage to streamline the delivery of multi-channel conversations to millions of people across the world

WASHINGTON & LONDON–(BUSINESS WIRE)–ContactEngine, the proactive conversational AI technology used by large corporations across industries to automate customer communications, has today announced a partnership with Vonage, a global cloud communications leader helping businesses accelerate their digital transformation, to navigate the delivery of its multi-channel conversations across the world.

Through this partnership, ContactEngine will augment Vonage’s own AI-powered solutions by providing access to its leading proactive conversational AI capabilities, which boasts 90% automation of customer conversations without the need for human intervention, alleviating call center pressure. ContactEngine achieves this through individually tailored conversations based on business objectives and intelligent call routing and escalation.

Through the Vonage Communications Platform, Vonage Application Programming Interfaces (APIs) will provide ContactEngine with the streamlined ability to overcome various regulations and complexities of delivering communications across all digital channels internationally. By leveraging Vonage APIs, ContactEngine conversations can be rapidly deployed across the globe, without the need for costly and disruptive software changes.

The partnership between Vonage and ContactEngine will allow for greater connectivity between brands and their customers, allowing businesses to enhance customer experience wherever they are in the world. The partnership also strengthens both Vonage and ContactEngine’s offerings on the international stage, with both businesses sharing their resources to meet customers’ demands, which have rapidly changed in an increasingly digital world that has only accelerated in the past 12 months due to Covid-19.

Prof. Mark K. Smith, Group CEO of ContactEngine, commented: “It’s a great privilege to be able to work with Vonage. ContactEngine operates internationally, engaging in millions of customer conversations for some of the biggest companies in the world. What’s so pleasing about partnering with Vonage is that we need to work right at the edges of perfection – if we can deliver even an extra 1% improvement in the way customers engage, then we can deliver considerable savings for a company – and Vonage offers us the path to realize that through their international reach, low latency, and ability to deliver communications across various channels. It’s a complex landscape communicating with customers on an international scale and Vonage gives us the confidence to operate with reliability.”

Sunny Rao, Vonage Senior Vice President, API Global Sales, also commented: “At Vonage, we’re accelerating the way the world connects as a leader in the Communications Platform as a Service (CPaaS) industry. We’ve built a number of market leading products around our messaging, voice and video APIs to support our customers in doing mission critical things on a global scale with impact. Our aim is to make it as easy as possible for them to accomplish that, by removing the intricate communication barriers which vary from country to country and network to network. Beyond providing our technology, we also have a collective mission with ContactEngine to enhance customer experiences, so I’m really looking forward to all the great things that we can do together.”

ContactEngine is already deployed by the top UK, European, and North American brands in telecommunications, utilities, financial services, auto and retail, including British Gas, BT, DHL, Sky, TELUS, Verizon, Virgin Media, and Whirlpool. The partnership with Vonage only strengthens ContactEngine’s international offering. To find out more about ContactEngine and its services, please visit contactengine.com.

About ContactEngine

ContactEngine is a Conversational AI technology that enables brands to proactively engage customers in conversations that fulfill business objectives. ContactEngine automates outbound customer engagement across all channels and generates unique insights into the changing patterns of communication by applying demographic and intent analysis, linguistics and ground-breaking artificial intelligence principles to mass volumes of raw data. ContactEngine transforms the way global brands engage with their customers – saving brands millions and making their customers happier. For more information about ContactEngine, please visit contactengine.com.

About Vonage

Vonage (Nasdaq: VG), a global cloud communications leader, helps businesses accelerate their digital transformation. Vonage’s Communications Platform is fully programmable and allows for the integration of Video, Voice, Chat, Messaging and Verification into existing products, workflows and systems. Vonage’s fully programmable unified communications and contact center applications are built from the Vonage platform and enable companies to transform how they communicate and operate from the office or anywhere, providing enormous flexibility and ensuring business continuity.

Vonage Holdings Corp. is headquartered in New Jersey, with offices throughout the United States, Europe, and Asia. To follow Vonage on Twitter, please visit twitter.com/vonage. To become a fan on Facebook, go to facebook.com/vonage. To subscribe on YouTube, visit youtube.com/vonage.

Maura Diamond

[email protected]

Phone: +44 (0) 7506040120

KEYWORDS: Europe United States United Kingdom North America District of Columbia

INDUSTRY KEYWORDS: VoIP Other Technology Technology Telecommunications Software

MEDIA:

Logo
Logo
Posted on

Advanced Sterilization Products Announces Aisha Barry as President

Advanced Sterilization Products Announces Aisha Barry as President

Barry Brings a Strong Background of Strategic Business Leadership and Technology Innovation

IRVINE, Calif. & EVERETT, Wash.–(BUSINESS WIRE)–
Advanced Sterilization Products (ASP), a global leader in infection prevention and a wholly owned operating company of Fortive Corporation (NYSE: FTV), has named Aisha Barry the new president of ASP.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210330005106/en/

Advanced Sterilization Products Announces Aisha Barry as President (Photo: Business Wire)

Advanced Sterilization Products Announces Aisha Barry as President (Photo: Business Wire)

“Aisha’s extensive healthcare background coupled with software and consumer products innovation will help strengthen ASP’s digital expertise, develop strategic alliances, and expand our international sales presence,” said Barbara Hulit, Sr. VP of Fortive’s Advanced Healthcare Solutions segment. “Aisha has a proven track record of developing highly effective organizations, leading to sustained growth. She will build on our current growth trajectory and advance the company’s mission to protect patients during their most critical moments.”

Aisha joins ASP from Philips, where her most recent role was Vice President and General Manager for the Patient Monitoring category. Before that, Aisha served as Vice President and General Manager of Patient Management Software for Medtronic. Other past experience includes leadership roles at John Deere and more than 12 years of marketing and product development roles at Procter & Gamble.

Aisha holds an MBA from Tuck School of Business at Dartmouth and a degree in chemical engineering from The Ohio State University.

About Advanced Sterilization Products (ASP)

Advanced Sterilization Products (ASP) has a long track record of designing and delivering innovative infection prevention solutions that dramatically raise the level of health care and safety for those who matter most. Our pioneering technology, global distribution and established leadership position enable us to simplify the process of buying and operating infection prevention products and services every day for thousands of medical facilities around the world. This enables our customers to focus on what they do best – preventing infection and saving lives. For more information, please visit www.asp.com.

©ASP 2021. All rights reserved.

MEDIA CONTACT:

Amy Higgins

Director of Communications

[email protected]

INVESTOR RELATIONS:

Griffin Whitney

Vice President, Investor Relations

Fortive Corporation

[email protected]

KEYWORDS: United States North America California Washington

INDUSTRY KEYWORDS: General Health Medical Devices Infectious Diseases Hospitals Health

MEDIA:

Logo
Logo
Photo
Photo
Advanced Sterilization Products Announces Aisha Barry as President (Photo: Business Wire)
Posted on

NAFCU Services Announces Persistent Systems as Preferred Partner for Digital Transformation including Cloud-Based Technologies

NAFCU Services Announces Persistent Systems as Preferred Partner for Digital Transformation including Cloud-Based Technologies

ARLINGTON, Va.–(BUSINESS WIRE)–NAFCU Services announced today that Persistent Systems (BSE and NSE: Persistent) has become the newest Preferred Partner to join its program serving credit unions.

Through this partnership, credit unions will have greater access to Persistent’s strategic technology services and solutions to accelerate digital transformation, including expanding the use of cloud-based technologies. The partnership was approved following a rigorous, independent review and voting process by credit union executives.

Persistent delivers world-class digital solutions to help credit unions accelerate their digital strategy to improve member experience and reduce costs. Persistent understands the unique obstacles that credit unions face and provides strategic advisory services to help grow their institutions and provide a differentiated experience for members.

“We are excited to welcome Persistent as a new partner to this program,” said Randy Salser, president of NAFCU Services. “Adoption of cloud and other cutting edge technologies including machine learning, automation, and artificial intelligence have rapidly become necessary for so many credit union functions. A partner like Persistent can help our industry continue to grow and innovate with proven technologies and practices.”

In 2019, Persistent Systems launched the Persistent Digital Credit Union Solution which enables credit unions to extend their existing IT investments to set up digital banking initiatives leveraging cloud based technologies to more rapidly launch new products and service offerings. Additionally, Persistent maintains extensive partnership agreements with leading FinTech ISVs, empowering credit unions to deliver cutting edge member experiences.

“Credit unions play a critical role in society; and enabling them to use best-of-breed technology to better serve their members and grow their reach is a core part of our business,” said Bipin Sahni, Chief Strategy Officer, BFSI for Persistent. “We’re proud to partner with NAFCU so we can help even more credit unions quickly launch new digital capabilities.”

About NAFCU Services

As part of the National Association of Federally-Insured Credit Unions, NAFCU Services provides funding, educational content, and a portfolio of trusted and vetted Preferred Partners.

For 40+ years, we’ve served credit unions across the country. Our team of partners delivers groundbreaking ideas and next-gen solutions, enabling credit unions to compete, change the status quo, and grow their institutions. For more information, visit our website and follow us on Twitter.

About Persistent

With 12,000+ employees around the world, Persistent Systems (BSE & NSE: PERSISTENT) is a global solutions leader that has been delivering digital business acceleration, enterprise modernization and next-generation product engineering to financial services institutions for 20+ years, as well as other industry verticals. To learn more about our credit union solutions visit our website.

NAFCU Services Contact:

Paul Timm

[email protected]

Persistent Contact:

Emma Handler

[email protected]

KEYWORDS: United States North America Virginia

INDUSTRY KEYWORDS: Other Consumer Security Other Technology Software Other Policy Issues Finance Networks Consulting Internet Banking Consumer Accounting Professional Services Technology Mobile/Wireless Public Policy/Government Public Relations/Investor Relations Communications Small Business

MEDIA:

Logo
Logo
Posted on

Motorola Solutions’ New Feature Enables Officers to Activate Body-Worn Camera Through Radio

Motorola Solutions’ New Feature Enables Officers to Activate Body-Worn Camera Through Radio

The radio integration provides officers with a more intuitive way to capture evidence easily in emergency situations, enhancing transparency throughout communities

CHICAGO–(BUSINESS WIRE)–Motorola Solutions (NYSE: MSI), today announced a new integration between its V300 body-worn cameras and mission-critical APX® Project 25 (P25) two-way radios. Video serves as a crucial piece of evidence for law enforcement while also serving as an essential ingredient for building trust and transparency with the communities they protect. The integration is designed to automate officer tasks and capture evidence in their most critical moments by activating a body-worn camera recording when an officer triggers the emergency mode on their radio.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210330005169/en/

V300/APX radio integration (Photo: Business Wire).

V300/APX radio integration (Photo: Business Wire).

For example, an officer who may come under attack will need to call for backup, but will also need to keep their full focus on their assailant. By pressing the emergency button on their radio, the officer is able to alert the dispatcher of their situation and, simultaneously, begin recording on the body-worn camera so that a real-time, unbiased perspective into the evolving situation is captured. If the body-worn camera is connected to the officer’s 4RE® In-Car Video Camera System, or their partners’ body-worn cameras, these will also start recording.

“When your life is in danger, it’s not the time to have to go through a checklist. Officers are frequently put in stressful positions where they need to have absolute focus,” said John Kedzierski, senior vice president, Video Security & Analytics at Motorola Solutions. “We believe that technology should help automate officer tasks, like activating a body-worn camera recording when certain triggers are received, so that critical moments are not missed during these high-stress situations.”

Two-way radios are universally deployed devices that are foundational to officer safety, allowing law enforcement to communicate effectively and efficiently with their teams. By integrating APX radios with body-worn cameras, Motorola Solutions is breaking down system silos and enabling officers to rely on the technology and workflows that they instinctively use as incidents unfold.

This integration is one of many introduced by the company to automate officer tasks and capture critical evidence. Other automated tasks include activating the V300 body-worn camera and 4RE In-Car Video Camera System when an officer steps out of the vehicle, when the vehicle exceeds a certain speed or when the lights and sirens on a vehicle are turned on. These integrations continue to make it easier for officers to gather information in the field while remaining focused on the tasks in front of them.

Motorola Solutions is dedicated to bringing law-enforcement technologies together so that the devices, systems and software that public safety uses are complementary and seamlessly integrated. The new feature will be available on Motorola Solutions’ industry-leading radios, including APX NEXT, APX 8000, 7000, 6000, and 4000 series.

About Motorola Solutions

Motorola Solutions is a global leader in mission-critical communications and analytics. Our technologies in land mobile radio mission-critical communications, command center software, video security & analytics, bolstered by managed & support services, make communities safer and help businesses stay productive and secure. At Motorola Solutions, we are ushering in a new era in public safety and security. Learn more at www.motorolasolutions.com.

MOTOROLA, MOTOROLA SOLUTIONS and the Stylized M Logo are trademarks or registered trademarks of Motorola Trademark Holdings, LLC and are used under license. All other trademarks are the property of their respective owners. ©2021 Motorola Solutions, Inc. All rights reserved.

Media Contact

Elyssa Macfarlane

[email protected]

604 629 5182 ext 2303

KEYWORDS: United States North America Illinois

INDUSTRY KEYWORDS: Mobile/Wireless Technology Homeland Security Other Technology Law Enforcement/Emergency Services Telecommunications Public Policy/Government Audio/Video Hardware State/Local

MEDIA:

Logo
Logo
Photo
Photo
V300/APX radio integration (Photo: Business Wire).
Posted on

fuboTV Appoints Ali Ghanavati, Head of Regulatory Technology, Fubo Gaming

 fuboTV Appoints Ali Ghanavati, Head of Regulatory Technology, Fubo Gaming

NEW YORK–(BUSINESS WIRE)–
fuboTV Inc. (NYSE: FUBO), the leading sports-first live TV streaming platform, has named Ali Ghanavati as head of regulatory technology for its new Fubo Gaming subsidiary. Ghanavati’s extensive gaming career includes roles as chief engineer and as deputy chief of the Technical Services Bureau (Gaming Laboratory) of the State of New Jersey Division of Gaming Enforcement, where he consulted with numerous state agencies and gaming jurisdictions regarding casino gaming regulation and standards. He joins Fubo Gaming effective immediately.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210330005046/en/

In his new role, Ghanavati will collaborate with Fubo Gaming’s Chief Operating Officer Sam Rattner and the broader management team on both building new and innovative consumer experiences across video and wagering as well as obtaining the requisite state regulatory approvals for each initiative. Ghanavati, who has deep experience across many aspects of technological regulation in the gaming industry (online casino, land-based casino, sports wagering, eSports and daily fantasy sports), will oversee product and technology standards in those jurisdictions where Fubo Gaming’s forthcoming Fubo Sportsbook will be available. The company expects to launch its sportsbook in the fourth quarter of 2021, subject to obtaining requisite regulatory approvals.

“Successfully navigating the gaming industry’s complex regulatory process is critical as we work towards the launch of Fubo Sportsbook,” said Rattner. “I’m thrilled Ali, who has decades of experience and strong relationships across the industry, will lead the product and technology processes for Fubo Gaming.”

“I am truly elated to be joining the Fubo Gaming team,” said Ghanavati. “The company’s vision of integrating gaming with a live TV streaming video platform is different than anything currently on the market. I look forward to working with Sam and his team and being part of the next phase of gaming.”

Ghanavati previously spent over a decade at Gaming Laboratories International (GLI), which provides the gaming industry’s leading testing and certification services. His most recent role at GLI, as gaming development representative, included leading and guiding operators and developers to successfully launch products in various gaming channels. Prior to GLI, Ghanavati spent over 20 years with the Technical Services Bureau (Gaming Laboratory) of the State of New Jersey Division of Gaming Enforcement, most recently as deputy chief where he managed the Bureau’s personnel and operations. He began his career on the Technical Services Bureau’s engineering team, ultimately rising to chief engineer.

About Fubo Gaming

Fubo Gaming Inc. is a subsidiary of fuboTV (NYSE: FUBO), the sports-first live TV streaming platform. Complementing fuboTV’s leading sports streaming platform, Fubo Gaming aims to provide a comprehensive sports and entertainment experience through sports betting and interactive gaming. The online wagering experience, Fubo Sportsbook, is expected to launch in Q4 2021, subject to obtaining requisite regulatory approvals.

About fuboTV

With a mission to provide the world’s most thrilling sports-first live TV experience through the greatest breadth of premium content, interactivity and integrated wagering, fuboTV Inc. (NYSE: FUBO) is focused on bringing to life its vision of a streaming platform that transcends the industry’s current virtual MVPD model. fuboTV Inc. operates in the U.S., Canada and Spain.

Leveraging its proprietary data and technology platform optimized for live TV and sports viewership, fuboTV Inc. aims to turn passive viewers into active participants. Through its cable TV replacement product, fuboTV, subscribers can stream a broad mix of 100+ live TV channels, including 42 of the top 50 Nielsen-ranked networks across sports, news and entertainment — more than any other live TV streaming platform (source: Nielsen Total Viewers, 2020). fuboTV intends to add interactivity to its streaming experience with the launch of a predictive free-to-play gaming app in Q3 2021.

Fubo Gaming Inc., a subsidiary of fuboTV Inc., expects to launch Fubo Sportsbook, a comprehensive sports and entertainment experience through sports betting and interactive gaming, in Q4 2021, subject to obtaining requisite regulatory approvals.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on the current beliefs, expectations and assumptions of fuboTV and on information currently available to fuboTV. The forward-looking statements in this press release represent fuboTV’s views as of the date of this press release. These statements may include, but are not limited to, statements regarding future events or future financial and operating performance and fuboTV’s plans for, and the anticipated benefits of, and new strategic partnerships. Although fuboTV believes the expectations reflected in such forward-looking statements are reasonable, fuboTV can give no assurance that such expectations will prove to be correct. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause fuboTV’s actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. Accordingly, readers are cautioned not to place undue reliance on these forward-looking statements. Except as required by applicable law, fuboTV does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. Important factors that could cause fuboTV’s actual results to differ materially are detailed from time to time in the reports fuboTV files with the Securities and Exchange Commission, copies of which are available on the Securities and Exchange Commission’s website at www.sec.gov and are available from fuboTV without charge. However, new risk factors and uncertainties may emerge from time to time, and it is not possible to predict all risk factors and uncertainties.

fuboTV Investor and Media Contacts

Media Contacts:

Jennifer L. Press

[email protected]

Katie Minogue

[email protected]

Investor Contact:

The Blueshirt Group for fuboTV

[email protected]

KEYWORDS: United States North America New York

INDUSTRY KEYWORDS: Sports Casino/Gaming Entertainment TV and Radio General Sports

MEDIA:

Logo
Logo
Logo
Logo
Posted on

Sonatype’s Channel Partner Program Experiences Triple Digital Growth in EMEA For the Second Year Running

Channel-first strategy, including investment in strategic hires, tooling and infrastructure dramatically increases revenue and market penetration across the region

LONDON, March 30, 2021 (GLOBE NEWSWIRE) — Sonatype, the leader in developer-friendly tools for software supply chain management and security, today announced its EMEA partner program saw a 200% revenue increase in 2020. In a year that tested business strategies around the world, Sonatype’s channel-first approach propelled the company’s success as organizations continued to recognize the business-critical role of managing third-party open source and software supply chains. 

To further support its growing channel-first strategy in EMEA, Sonatype has announced a new program to provide the Sonatype channel community, from Distributors to System Integrators to Value Added Resellers (VARS), with resources to expand their customer base, enhance new revenue streams and increase profits – all while meeting growing  demand for DevOps and developer solutions. Additional programs include implementing new, integrated training enablement technologies, self-serve data intelligence, and go-to-market support. 

“We’ve always recognised the importance of a strong partner ecosystem in EMEA, but as our channel partner’s business continues to evolve, we’ve doubled-down on our investment to accelerate our channel first strategy in the region,” said Wai Man Yau, General Manager, International. ”The channel is instrumental to Sonatype’s growth. All of our partners play a vital role in our success, which is why we’ve added the equivalent of 100 people to our EMEA partner program in the last year alone.” 

The news comes at an exciting time for Sonatype, which just announced the acquisition of MuseDev, an innovative code analysis platform, and unveiled the next-generation of its Nexus platform. Sonatype’s industry first solutions now enable full-spectrum control of the cloud-native software development lifecycle including: third-party open source code, first-party source code, infrastructure as code (IaC), and containerized code. 

“More organizations have started understanding the importance of managing risks around all stages of the modern software development lifecycle,” said Luke Hasty, VP Strategy of Sonatype partner, Nuaware. “Sonatype has helped us provide customers with the best possible open source intelligence and security, solving a core set of problems their developers face. With Sonatype’s new full-spectrum software supply chain management system, we’ll now be able to completely change the game and truly transform the way our distribution channel and customers develop applications.”

As Sonatype and Exclusive Networks accelerate their relationship, Denis Ferrance, Vice President, Global Vendor’s Alliances & Business Development at Exclusive Networks added, “As a partner, the Sonatype team consistently goes above and beyond to help us educate our resellers, the market and our customers, which in turn makes our jobs exponentially easier. It can be rare to find such a symbiotic relationship, we’re proud to be a part of Sonatype’s team and help expand its footprint far and wide.”

Further, success in the EMEA partner program mirrors the success the company is having globally. Sonatype now counts 70% of the Fortune 100 as customers and supports more than 2,000 commercial engineering teams. Further, in 2020, Sonatype experienced 35% annual growth in Nexus Repository installs, which now total more than 250,000 instances. Today, the combination of Sonatype’s commercial and open source tools are trusted by nearly 15 million developers around the world. 

Sonatype is continually looking to grow its partner ecosystem. To learn more about becoming a Sonatype partner or to see who the company is working with, visit https://www.sonatype.com/partners.

About Sonatype: 

Sonatype is the leader in developer-friendly, full-spectrum software supply chain management providing organizations total control of their cloud-native development lifecycles, including third-party open source code, first-party source code, infrastructure as code, and containerized code. The company supports 70% of the Fortune 100 and its commercial and open source tools are trusted by 15 million developers around the world. With a vision to transform the way the world innovates, Sonatype helps organizations of all sizes build higher quality software that’s more aligned with business needs, more maintainable, and more secure. 

Sonatype has been recognized by Fast Company as one of the Best Workplaces for Innovators in the world, two years in a row and has been named to the Deloitte Technology Fast 500 and Inc. 5000 list for the past five years. For more information, please visit Sonatype.com, or connect with us on Facebook, Twitter, or LinkedIn.



Elissa Walters
Sonatype
480-818-0734
[email protected]

Posted on

Trinity Biotech Announces the Submission of TrinScreen™ HIV to the World Health Organisation for Approval

DUBLIN, Ireland, March 30, 2021 (GLOBE NEWSWIRE) — Trinity Biotech plc (Nasdaq: TRIB) has submitted its new HIV screening product, TrinScreen™ HIV, to the World Health Organisation (WHO) for approval.

This product, once approved, will allow the Company to build on its strong presence in HIV testing in Africa, with the Company having been the main confirmatory test provider over many years with its Uni-Gold™ HIV test.

It is expected that the WHO will take a number of months to consider the submission. The Company intends to use that time to prepare for automated manufacturing of the test at the Company’s facility in Ireland.

Test Overview

The product is designed to test for the presence of HIV antibodies from a finger stick sample of blood, in less than 12 minutes. The test has been designed to maximise assay sensitivity and ease of use in the field. A high assay sensitivity indicates the potential risk of a false negative result is very low – a critical parameter in screening programmes where the objective is to identify those with HIV infection. Ease of use in the field allows for broad dissemination of testing which is of critical importance in the African HIV testing market.

Performance Evaluation

As part of the WHO approval process the product has already undergone an evaluation sponsored by the WHO with 1,200 clinical samples at an independent laboratory. The results of this evaluation were excellent. In addition to this, the full submission for pre-qualification also includes the data from a multi-centre clinical evaluation which concluded in Africa in 2020.

Comments

Commenting, Ronan O’Caoimh, Chief Executive Officer stated, “We are excited to have submitted our new HIV screening product, TrinScreen HIV, to the WHO for approval. The development of this product has been a strategic priority for Trinity Biotech over several years. It is very positive to see this project reach such a key milestone, especially given the challenges caused by COVID-19 to the clinical evaluation process. Trinity Biotech has already earned a strong reputation in the HIV testing market in Africa with our HIV confirmatory test, Uni-Gold HIV. We expect that on approval by the WHO of TrinScreen HIV, Trinity Biotech will be ideally positioned to take a significant share of the HIV screening market in Africa given the excellent clinical performance of the product and our existing strong reputation in the HIV testing market in Africa.”

Forward Looking Statements

Certain statements made in this release that are not historical are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words “estimate”, “project”, “intend”, “expect”, “believe” and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties. Many factors could cause the actual results, performance or achievements of Trinity Biotech to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements, including, but not limited to, the results of research and development efforts, risks associated with the outbreak and global spread of the coronavirus (COVID-19), the effect of regulation by the U.S. Food and Drug Administration and other agencies, the impact of competitive products, product development commercialization and technological difficulties. For additional information regarding these and other risks and uncertainties associated with Trinity Biotech’s business, reference is made to our reports filed from time to time with the U.S. Securities and Exchange Commission. We undertake no obligation to update or revise any forward-looking statements for any reason.

About Trinity Biotech

Trinity Biotech develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market. The products are used to detect infectious diseases and to quantify the level of Haemoglobin A1c and other chemistry parameters in serum, plasma and whole blood. Trinity Biotech sells direct in the United States, Germany, France and the U.K. and through a network of international distributors and strategic partners in over 75 countries worldwide. For further information please see the Company’s website:www.trinitybiotech.com.

Contact: Trinity Biotech plc
Terence Dunne
(353)-1-2769800
E-mail: [email protected]



Posted on

Medical Marijuana, Inc. Subsidiary HempMeds® Welcomes X Games World Record-Holding Skateboarder Italo Penarrubia as Newest Brand Ambassador

SAN DIEGO, March 30, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — Medical Marijuana, Inc. (OTC: MJNA) (the “Company”), the first-ever publicly traded cannabis company in the United States that launched the world’s first-ever cannabis-derived nutraceutical products, brands and supply chain, announced today that its subsidiary HempMeds® is proud to welcome X Games world record-holding skateboarder Italo Penarrubia as its newest brand ambassador.

“We are excited to bring Penarrubia on as a part of our team and it is heart-warming to know how much our products have helped him over the years. We believe his support and recognition will help us further educate athletes and the general public on the health and wellness benefits of hemp-based cannabidiol (CBD) products,” said HempMeds® CEO Raul Elizalde.

Penarrubia is a renowned skateboarder and has performed in several X Games competitions, including his most recent appearance in X Games Minneapolis in 2019. At the 2017 X Games in Minneapolis, he earned a world record for the highest SKB Big Air height ever recorded at the X Games. After spending several years training in the U.S., Penarrubia recently relocated back to Brazil to continue his career and raise his family.

“I have been using HempMeds’ CBD products for years to aid in recovery after long days of training,” said Penarrubia. “My goal is to help bridge the knowledge gap for athletes around the world that could benefit from using CBD but are afraid or unsure of how to use the products.”

To learn more about HempMeds®, please visit the Company online at www.hempmedspx.com. 

About HempMeds®
Founded in 2012, HempMeds® was the first company to bring hemp-based cannabidiol (CBD) oil products to market in the U.S. As a subsidiary of Medical Marijuana, Inc., HempMeds is the exclusive distributor for premium brands including Real Scientific Hemp Oil™ and Dixie Botanicals®, and operates in all 50 states and 40 countries. HempMeds® is the only company to have its CBD products listed in the Prescribers’ Digital Reference (PDR), the only company invited to speak to the World Health Organization and FDA on the benefits of CBD, and one of the first to be certified by the U.S. Hemp Authority. To learn more, please visit www.hempmedspx.com.

About Medical Marijuana, Inc.
We are a company of firsts®. Medical Marijuana, Inc. (MJNA) is a cannabis company with three distinct business units in the non-psychoactive cannabinoid space: a global portfolio of cannabinoid-based nutraceutical brands led by Kannaway® and HempMeds®; a pioneer in sourcing the highest-quality legal non-psychoactive cannabis products derived from industrial hemp; and a cannabinoid-based clinical research and botanical drug development sector led by its pharmaceutical investment companies and partners including AXIM® Biotechnologies, Inc. and Kannalife, Inc. Medical Marijuana, Inc. was named a top CBD producer by CNBC. Medical Marijuana, Inc. was also the first company to receive historic import permits for CBD products from the governments of Brazil, Mexico, Argentina, and Paraguay and is a leader in the development of international markets. The company’s flagship product Real Scientific Hemp Oil has been used in several successful clinical studies throughout Mexico and Brazil to understand its safety and efficacy.

Medical Marijuana, Inc.’s headquarters is in San Diego, California, and additional information is available at OTCMarkets.com or by visiting www.medicalmarijuanainc.com. To see Medical Marijuana, Inc.’s corporate video, click here.

Shareholders and consumers are also encouraged to buy CBD oil and other products at Medical Marijuana, Inc.’s shop.

FORWARD-LOOKING DISCLAIMER
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.

FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

LEGAL DISCLOSURE
Medical Marijuana, Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act.

CONTACT:

Public Relations Contact:
Kathryn Brown
Account Supervisor
CMW Media
P. 858-264-6600
[email protected]
www.cmwmedia.com

Investor Relations Contact:
P. (858) 283-4016
[email protected]

Attachment



Posted on

Rafael Pharmaceuticals Crosses Enrollment of 150 Patients in Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613® (Devimistat) for Relapsed or Refractory Acute Myeloid Leukemia (AML)

Company meets enrollment milestones to support research and development of a new and novel treatment for hard-to-treat cancer

CRANBURY, N.J., March 30, 2021 (GLOBE NEWSWIRE) — Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced that it has crossed the enrollment of 150 patients in its Phase 3 clinical trial for patients with relapsed or refractory acute myeloid leukemia (AML) (ARMADA 2000). The multicenter, open-label, randomized pivotal trial is assessing the efficacy and safety of Rafael’s lead compound CPI-613® (devimistat) in combination with high dose cytarabine and mitoxantrone (CHAM) compared to high dose cytarabine and mitoxantrone (HAM) therapy in older patients. The announcement comes on the heels of the Company’s achievement in receiving FDA fast-track designation for CPI-613® (devimistat) in the treatment of AML, at the end of 2020.

“Every enrollment is an opportunity for us to hope for the future of this therapy for very hard-to-treat cancers,” said Sanjeev Luther, President and CEO of Rafael Pharmaceuticals. “The pace at which we are enrolling patients demonstrates the need for more effective AML treatments, and we have so much appreciation for the caregivers, patients, primary investigators and Rafael employees who contributed to help us surpass this important milestone.”

There are currently no standard therapy for AML patients who suffer a relapse, and the prognosis for older patients is grim.

“The need for new and novel treatments in AML continues to grow alongside the estimated incidence rate,” said Richard Larson, M.D., Director of the Hematologic Malignancies Program at the University of Chicago Medical Center and a principal investigator on the Phase 3 clinical trial. “As patients face a diagnosis with relapsed or refractory AML, the potential of these treatments is incredibly important.”

“Having Dr. Larson and other leading clinicians contributing to the enrollment growth of this trial is immensely helpful,” said Timothy S. Pardee, M.D., Ph.D., Co-Chief Medical Officer of the Company. “Ultimately, it is these milestones that will shepherd us towards finding treatment options for patients who need them most.”


About CPI-613® (devimistat) 


CPI-613® (devimistat) is a first-in-class clinical lead compound of Rafael, which targets enzymes that are involved in cancer cell energy metabolism and are located in the mitochondria of cancer cells. Devimistat is designed to target the mitochondrial tricarboxylic acid (TCA) cycle, a process essential to tumor cell multiplication and survival, selectively in cancer cells. Devimistat substantially increases the sensitivity of cancer cells to a diverse range of chemotherapeutic agents. This synergy allows for potential combinations of devimistat with lower doses of these generally toxic drugs to be more effective with lower patient’s side effects. Combination with devimistat represent a diverse range of opportunities to substantially improve patient’s benefit in many different cancers. The U.S. Food and Drug Administration (FDA) has given Rafael approval to initiate pivotal Phase 3 clinical trials in pancreatic cancer (AVENGER 500) and acute myeloid leukemia (ARMADA 2000), and has designated devimistat as an orphan drug for the treatment of pancreatic cancer, acute myeloid leukemia, myelodysplastic syndrome, peripheral T-cell lymphoma and Burkitt’s lymphoma. The EMA has granted orphan drug designation to devimistat for pancreatic cancer and acute myeloid leukemia.


About Rafael Pharmaceuticals, Inc.


Rafael Pharmaceuticals is a leader in the growing field of cancer metabolism. The company is developing a new, first-in-class category of metabolic oncology therapeutics that attack hard-to-treat cancers by targeting the metabolic processes the disease needs to survive, grow and proliferate. Rafael Pharmaceuticals’ lead compound, CPI-613® (devimistat), is a highly selective, well-tolerated and effective anti-cancer agent that is being evaluated in ongoing and completed Phase 1, 2 and 3 clinical trials. Devimistat has been granted orphan drug status by the FDA for the treatment of pancreatic cancer, acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and Burkitt’s, peripheral T-cell lymphomas and soft tissue sarcoma. The Company’s investors include Rafael Holdings, Inc. (NYSE AMERICAN: RFL). For more information, please visit www.rafaelpharma.com.


Safe Harbor Statement


This press release contains forward-looking statements. These statements relate to future events or the company’s future financial performance. In some cases, you can identify forward-looking statements by terminology such as “may”, “will”, “should”, “expect”, “plan”, “anticipate”, “believe”, “estimate”, “predict”, “potential” or “continue”, the negative of such terms, or other comparable terminology. These statements are only predictions. Actual events or results may differ materially from those in the forward-looking statements as a result of various important factors. Although we believe that the expectations reflected in the forward-looking statements are reasonable, such statements should not be regarded as a representation by the company, or any other person, that such forward-looking statements will be achieved. The business and operations of the company are subject to substantial risks which increase the uncertainty inherent in forward-looking statements. We undertake no duty to update any of the forward-looking statements, whether as a result of new information, future events or otherwise.

In light of the foregoing, readers are cautioned not to place undue reliance on such forward-looking statements.

###


Rafael Media Contact:


Diana Cleinmark
[email protected]
(408) 713-1216